Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PRKACG | P22612 | 1/20 | 0.42 |
| ▸ | PRKACB | P22694 | 1/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618907 | 0.80 | BRD4 (0.48) | BRD4CDK9FLT3MKNK1MKNK2 | |
| SCHEMBL3623722 | 0.79 | EIF2AK2 (0.55) | BRD4CDK9FLT3MKNK1MKNK2 | |
| SCHEMBL3617870 | 0.78 | EIF2AK2 (0.59) | BRD4CDK9ABL1BCRPRKCA | |
| SCHEMBL14123853 | 0.77 | CDK1 (0.64) | BRD4CDK9FLT3MKNK1MKNK2 | |
| SCHEMBL3618940 | 0.75 | PIK3CD (0.50) | BRD4CDK9FLT3PRKCAPRKACA | |
| SCHEMBL15124961 | 0.74 | PRKCD (0.50) | ABL1PRKCAPRKACAPRKCDEGFR | |
| SCHEMBL3618475 | 0.73 | CDK1 (0.60) | FLT3MKNK2PRKACAPRKCDEIF2AK2 | |
| SCHEMBL3620128 | 0.73 | CDK9 (0.64) | BRD4CDK9FLT3ABL1BCR | |
| SCHEMBL3615777 | 0.72 | GSK3B (0.67) | CDK9PRKACAPRKACGPRKACBPIK3CD | |
| SCHEMBL3812805 | 0.71 | MAPK8 (0.42) | BRD4CDK9FLT3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| WO-2008079918-A1 | INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | BRD4 2447/4885CDK9 3238/4885FLT3 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.